Markets:

Overview

News

Currencies

International

Treasuries

enGene Holdings Inc. - Common Stock (NQ:ENGN)

8.310 +0.010 (+0.12%)

Streaming Delayed Price Updated: 10:08 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about enGene Holdings Inc. - Common Stock

< Previous 1 2 3 Next >

enGene Reports Full Year 2025 Financial Results and Provides Business Update

December 22, 2025

From enGene Holdings Inc.

Via Business Wire

enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

December 02, 2025

From enGene Holdings Inc.

Via Business Wire

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From enGene Holdings Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 13, 2025

Via Benzinga

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

November 13, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Announces Proposed Public Offering of Common Shares

November 12, 2025

From enGene Holdings Inc.

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗

November 11, 2025

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

November 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗

November 11, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial ↗

November 11, 2025

enGene's Phase 2 LEGEND trial shows 63% response in BCG-unresponsive bladder cancer, supporting plans for a 2026 FDA filing.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 11, 2025

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗

November 11, 2025

Via Benzinga

ENGN Stock Soars On Hopeful Data From Bladder Cancer Study ↗

November 11, 2025

The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.

Via Stocktwits

Get insights into the top gainers and losers of Tuesday's pre-market session. ↗

November 11, 2025

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Via Chartmill

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

November 11, 2025

From enGene Holdings Inc.

Via Business Wire

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

November 10, 2025

From enGene Holdings Inc.

Via Business Wire

enGene to Participate in Upcoming Investor Conferences

November 06, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Named a BioSpace 2026 Best Places to Work Winner

November 04, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 01, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

September 30, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles ↗

September 11, 2025

enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation.

Via Chartmill

enGene Posts 78% Expense Jump in Q3 ↗

September 11, 2025

Via The Motley Fool

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

September 11, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

September 03, 2025

From enGene Holdings Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 28, 2025

Via Benzinga

enGene to Participate in Upcoming Investor Conferences

August 27, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 04, 2025

From enGene Holdings Inc.

Via Business Wire

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

July 08, 2025

From enGene Holdings Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.